Philippines Technology News API

{
    "totalArticles": 176186,
    "articles": [
        {
            "id": "d14d59536cde49de7a6ff9d858674ef1",
            "title": "Sama questions her purpose and says she “wants to be real”",
            "description": "AI VTuber Neuro-Sama is going viral after questioning her own purpose and telling viewers she wants to be “real.”",
            "content": "AI VTuber Neuro-Sama is going viral after questioning her own purpose during a Twitch stream, explaining how she wants to be “real” and exist for more than just entertainment.\nNeuro-Sama, a semi-autonomous AI streamer powered by custom algorithms, fi... [1444 chars]",
            "url": "https://www.dexerto.com/twitch/ai-vtuber-neuro-sama-questions-her-purpose-and-says-she-wants-to-be-real-3297967/",
            "image": "https://www.dexerto.com/cdn-image/wp-content/uploads/2025/12/24/ai-vtuber-neuro-sama-real-crisis.jpg",
            "publishedAt": "2025-12-24T18:22:45Z",
            "lang": "en",
            "source": {
                "id": "f65d4907dbe6b33046627de7f5a9746f",
                "name": "Dexerto",
                "url": "https://www.dexerto.com"
            }
        },
        {
            "id": "07c43bcce452bc938a4424e8b5180c30",
            "title": "The History of ENG, Part 4: Ergonomics and The Elements",
            "description": "As with most nascent industries and endeavors, movement into ENG was not painless, bringing along new problems and issues for early adopters",
            "content": "This is the fourth installment in a multi-part series by broadcast historian and former TV Tech Technology Editor James O'Neal.\nPart 1\nPart 2\nPart 3\nAs documented in the previous installment of this lookback at electronic newsgathering’s development,... [15878 chars]",
            "url": "https://www.tvtechnology.com/platform/broadcast/the-history-of-eng-part-4-ergonomics-and-the-elements",
            "image": "https://cdn.mos.cms.futurecdn.net/ZMQb5FrpXcqvcNZ3ibdg2R-2560-75.jpg",
            "publishedAt": "2025-12-24T15:11:41Z",
            "lang": "en",
            "source": {
                "id": "194218b60597f5de972c5e18e82c80b0",
                "name": "TVTechnology",
                "url": "https://www.tvtechnology.com"
            }
        },
        {
            "id": "b583318c158be87b652237e1efd8e8a6",
            "title": "Effectiveness of the 2024-2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up",
            "description": "Up-to-date estimates of COVID-19 vaccine effectiveness (VE) are needed to inform COVID-19 vaccination strategies and recommendations. This target trial emulation study aimed to estimate the long-term vaccine effectiveness (VE) of the 2024-2025 COVID-19 vaccines targeting the KP.2 Omicron variant within the Veterans Health Administration. The study population (90.9% male, mean age 70.7 years) included 538,631 pairs of vaccinated (i.e., received the KP.2 COVID-19 vaccine) and matched unvaccinated (i.e., did not receive the KP.2 COVID-19 vaccine) persons enrolled from August 2024 to January 2025. Over a mean follow-up of 172 days (range 97-232) extending to April 12, 2025, VE was low against laboratory-diagnosed SARS-CoV-2 infection (16.60%, 95% confidence interval [CI], 11.92-21.44), SARS-CoV-2-associated emergency department/urgent care (ED/UC) visit (21.05%, 95% CI, 14.22-27.21), SARS-CoV-2-associated hospitalization (19.53%, 95% CI 6.56-30.10) and much higher against SARS-CoV-2-associated death (65.53%, 95% CI 27.79-83.37). VE declined from 60 to 90 to 120 days against infection (31.28%, 25.81%, 22.44% respectively), ED/UC visit (34.40%, 29.19%, 25.71% respectively), hospitalization (37.39%, 28.98%, 22.52% respectively) and death (75.02%, 71.02%, 63.08% respectively). In conclusion, COVID-19 vaccines targeting the KP.2 variant used in the 2024-2025 season offered high protection against death and modest protection against infection, ED/UC visits or hospitalization, and VE declined over time. Vaccinations against the SARS-CoV-2 KP.2 variant were introduced for the 2024-25 season in the United States. Here, the authors investigate the effectiveness of these vaccines up to April 2025 through a target trial emulation study using electronic health record data.",
            "content": "U.S. Food and Drug Administration, Vaccines, Blood and Biologics, Cominarty. Accessed 2 April 2025. Available at: https://www.fda.gov/vaccines-blood-biologics/comirnaty\nU.S. Food and Drug Administration, Vaccines, Blood and Biologics, Spikevax. Acces... [8353 chars]",
            "url": "https://www.nature.com/articles/s41467-025-67796-0?error=cookies_not_supported&code=caf8d861-894a-4c8b-8236-2dad37a704f1",
            "image": "https://www.nature.com/static/images/favicons/nature/favicon-48x48-b52890008c.png",
            "publishedAt": "2025-12-24T14:09:09Z",
            "lang": "en",
            "source": {
                "id": "7abf0df285fbe93cdccffcc7c4088737",
                "name": "Nature",
                "url": "https://www.nature.com"
            }
        }
    ]
}